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ABSTRACT: 
Immunotherapy against amyloid-beta	   (Aβ) may improve rodent cognitive function by 
reducing amyloid neuropathology and is being validated in clinical trials with positive 
preliminary results. However, for a complete understanding of the direct and long-term 
immunization responses in the aged patient, and also to avoid significant side effects, 
several key aspects remain to be clarified. Thus, to investigate brain Aβ clearance and 
Th2 responses in the elderly, and the reverse inflammatory events not found in the 
immunized rodent, better Alzheimer’s disease (AD) models are required. In the aged 
familiar canine with a cognitive dysfunction syndrome (CDS) we describe the rapid 
effectiveness and the full safety profile of a new active vaccine candidate for human AD 
prevention and treatment. In these aged animals, besides a weak immune system, the 
antibody response activated a coordinated central and peripheral Aβ clearance, that 
rapidly improved their cognitive function in absence of any side effects. Our results also 
confirm the interest to use familiar dogs to develop innovative and reliable therapies for 
AD. 
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INTRODUCTION 
Alzheimer’s disease is characterized by the presence of intracellular neurofibrillary 
tangles and extracellular Aβ plaques, with Aβ monomers and oligomers resulting from 
the amyloid precursor protein (APP) processing [1]. In the AD amyloid hypothesis, the 
extracellular accumulation of soluble Aβ peptide leads to CNS formation of soluble 
oligomers, fibrils and amyloid plaques, and the distribution between brain and blood 
compartments, reflects the imbalance between Aβ production and clearance [2]. The 
Aβ fibril formation is currently considered a dynamic and reversible process, as Aβ 
fibrils are continuously dissolving and reforming [3]. Because AD stage severity 
correlates more with soluble Aβ brain levels than with Aβ plaque abundance [2,4,5], the 
amyloid monomers and oligomers are considered to be more toxic [1,6]. 
Blockade of the AD course at early phases through different immunological anti-Aβ  
strategies to interfere the amyloid peptide homeostasis have given promising results. 
For example, active immunization targeting Aβ peptide in AD Tg mice has 
demonstrated striking reductions in Aβ deposition and reduction of behavioral 
impairments [7–9], and the same was observed in human beings [10]. However, 
significant questions remain to be answered for a full understanding of the direct and 
long-term immunization responses, and to avoid significant side effects in trials 
conducted with human patients. Thus, the development of new active vaccines 
inducing both Aβ clearance and only Th2 responses in good AD models remain key 
issues to be solved [11,12]. 
Dog with cognitive dysfunction syndrome (CDS) is considered a suitable model to 
address these innovative therapies [13], because it spontaneously expresses several 
markers associated with the underlying pathology of sporadic AD. Control aged dog 
(over 7-8 years) is also considered quite unique to elucidate the amyloid hypothesis, 
since its CNS Aβ peptide accumulation is responsible for neuronal dysfunction and 
deregulation of the same specific cortical subsets of interneurons described in the aged 
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human [14–17]. In addition, these aged animals also bring multiple druggable targets 
for the identification of novel disease-modifying agents to interfere natural Aβ 
production, aggregation, clearance or the associated neurotoxic effects [18,19]. 
Compared to the aged housed dog, some familiar dogs develop geriatric behavioral 
changes that give rise to a specific CDS, also known as canine counterpart of senile 
dementia of the Alzheimer's type. Because of their many common hallmarks, CDS is 
presently considered a model of choice for Mild Cognitive Impairment (MCI) and AD 
research [15,20,21], and, in particular, for the development of anti-Aβ immunotherapy 
[13,22,23]. Diagnosed of graded cognitive dysfunctions by practicing neurology 
veterinarians, these animals are systematically and easily classified into well-
characterized homogenous groups with no variation due to their breed (including sex, 
size and genetic background) or familiar life conditions [24–26]. In this study, we took 
advantage of this familiar model to investigate the effectiveness and safety of new 
active amyloid vaccines. This study is aimed at increasing our understanding of how 
immunomodulation supports CNS Aβ clearance, how it relates to cognitive 
improvement, and how it supports a safe and effective new AD immunotherapy.  
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MATERIAL AND METHODS 
Vaccine preparation 
Three different fibrillar Aβ vaccines (v1, v2 and v3) were initially prepared with 100µg of 
either Aβ40 peptide (>95% purity; Genscript, NJ, USA) (v1), 100µg Aβx-40 peptide KLH 
conjugated (>95% purity; Anaspect, CA, USA) (v2), or 100µg of 2/3 Aβ40 combined with 
1/3 of the Aβx-40 peptide KLH conjugated (v3). Aβ40 and Aβx-40 peptides were initially 
dissolved with dimethyl sulfoxide (DMSO) (1mg/ml), aliquoted and stored at -20ºC. 
Once thawed, each solution was mixed with 1mg of alum hydroxide suspension 
(Sigma, Spain). After overnight (ON) incubation at 4ºC, a saline solution was added up 
to a volume of 1.5ml, previous to the subcutaneous (s.c.) immunization of the dog. 
Placebo animals only received a mixture of saline solution + alum hydroxide 
suspension. 
Human samples  
Brain tissue from AD patients, stage II according to the Braak & Braak scale [27] was 
obtained from the Neurological Tissue Bank of the Universitat de Barcelona, 
Barcelona, Spain. 5µm paraffin embedded slices from hippocampus and cerebral 
cortex were obtained for immunohistochemistry experiments.  
Animals  
To select the vaccine of major interest, 6 adult female New Zealand White rabbits 
weighing between 1.5-2 kg at the beginning of the study were immunized with one of 
the 3 vaccines following the protocol selected for dogs. They were kept on a 12h 
light/12 h dark cycle and housed with free access to food and water.  
The safety and immunization studies were performed in 36 dogs (12 housed beagle 
dogs + 24 familiar dogs). The 12 male housed beagle dogs from Harlan laboratories 
(Gannat, France), with an age ranging between 2 and 8 years at the beginning of the 
study, were housed in groups of three in 1.85m wide x 3m large buildings, and were 
	  	  
	  
6	  
daily fed with 340gr of Hill’s canine adult food. The 24 familiar dogs of different breeds, 
sex and age were classified into control and dogs with graded CDS (Table 1) by a 
veterinarian neurologist.  
All the animals were treated according to the European legislation on animal handling 
and experimentation (86/609/EU) and, with the formal agreement of the owners of the 
familiar dogs. Procedures were approved by the Ethics Committee of the University of 
Barcelona, Barcelona, Spain. All efforts were made to minimize animal suffering and to 
use no more than the number of animals needed to obtain reliable scientific data. 
Cognitive evaluation  
The cognitive status of all 24 familiar dogs was evaluated. A validated cognitive test of 
9 items adapted from the Mini-Mental State Examination (MMSE) and the Diagnostic 
and Statistical Manual of Mental Disorders (DSM IV) for AD was used in collaboration 
with the pet owners (Table 2) [13,21]. Based on the presence of established 
housetraining habits, disorientation in familiar surroundings, decreased activity, 
playfulness, vitality, decreased interaction with the owner, and modifications of the 
sleep/awake cycle, dogs were divided into two groups: Old Control dogs (OC) and CDS 
dogs. Depending on the dysfunction grade, the CDS group was subdivided into a group 
with light cognitive deficit (LCD) or severe cognitive deficit (SCD).  
Screening study 
For the screening study all the 36 dogs were classified following their age and cognitive 
status in Adult Control dogs (AC), OC and LCD or SCD (Table 1).  
For each dog, a biochemical and hematological profile was regularly performed that 
also included Aβ levels in blood and Cerebrospinal Fluid (CSF). The albumin coefficient 
reflecting the Blood-Brain-Barrier (BBB) integrity [28] was also calculated. All animals 
were also monitored for adverse reactions and the vaccine puncture zone was 
periodically revised.  
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Immunization study 
Following the recommendation of the Ethics Committee, the use of healthy adult and 
old familiar dogs as control animals for the immunization study had to be avoided as 
the following 21 dogs were considered sufficient to obtain reliable data: 9 housed 
beagle dogs as control group and 12 CDS familiar dogs, with the acceptation of their 
owners, as the Case group (Table 1). 
The study was performed over a period of 131 days, with 6 s.c. injections administered 
during a period of 51 days in the back of the neck (Fig.1). 6 housed beagle dogs were 
immunized with the v3 vaccine (Immunized AC) and 9 dogs CDS dogs were 
immunized (Immunized CDS). The remaining 3 housed adult beagles and 3 familiar 
dogs were included in the Placebo group (Table 1). Cognitive follow-up of all CDS 
animals was performed on a double blind basis at days 31, 51 and 131, by the 
veterinarian and the pet’s owner, and blood and CSF parameters were regularly 
evaluated (Fig.1).  
Blood and CSF extraction 
Serum and plasma were obtained after 5ml blood extraction from the animal jugular 
vein every 10 days until day 71, and then at day 131. Once collected in tubes (BD, NJ, 
USA) containing EDTA for plasma or clotting gel for serum, blood was centrifuged at 
3000rpm during 15 minutes, aliquoted and kept at -80ºC until use. CSF was collected 
under 10mg/kg of sodium thiopental (Thiobarbital, Braun Medical S.A., Spain) 
intravenous (i.v.) anesthesia. Then, dogs were intubated, and oxygen administered 
following induction. Monitoring devices were used to control heart rate, blood pressure 
and blood oxygenation. The dog’s coat was clipped and prepared for an aseptic 
procedure, and CSF collected (1ml/5kg) by cisternal puncture into a sterile glass tube. 
Afterwards, it was divided into 0.5ml aliquots and quickly stored at - 80°C until use.  
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Biochemical and hematological analysis 
Biochemical parameters were analyzed by spectrophotometry (DIRUI CS-800, RAL, 
Barcelona, Spain) and hematological parameters were measured by laminar flow 
impedance (Procyte DX, Barcelona, Spain) (Table 3). The albumin quotient (Qalb) was 
calculated as the quotient between the albumin CSF (mg/L) and blood (g/L) 
concentration. CSF albumin was quantified by immunonephelometry (BN2, Siemens, 
Marburg, Germany) and serum albumin with the colorimetric bromocresol method 
(ADVIA 1800, Siemens diagnostic, Marburg, Germany). 
Anti-Aβ IgG titration  
For the rabbit anti-Aβ IgG titration, a Maxisorb 96 well plate (Nunc, Langenselbold, 
Germany) was coated ON at 4ºC with 100µl of Aβ40 diluted at 2µg/ml in NaHCO3. After 
a wash with 200µl of Phosphate buffer saline 100mM, pH 7.4 + 0.05% Tween (PBST), 
the plate was blocked during 2h at room temperature (RT) with PBS-bovine serum 
albumin (BSA) 5%. 100µl of rabbit serum from the different time points was diluted 
1/100 with PBS-BSA 5% and added to the wells after 3 washes during 2h at RT. In 3 
wells, only diluted PBS was added as a background reference. After 4 washes the 
biotin anti-rabbit IgG (Sigma Aldrich, MO, USA) diluted at 1/20000 was added for 1h at 
RT. Finally, and after 5 washes, extrAvidin peroxidase 1/200 was added for 30min and 
developed with 100µl of 3,3',5,5' tetramethylbenzidine (TMB) during 5 min. The 
reaction was stopped with 100µl H2SO4 100mM, and the optical density (OD) registered 
at 450nm (Tecan, Männedorf, Switzerland).  
For the dog serum and CSF anti-Aβ IgG titration, a Maxisorb 96 well plate was also 
used and coated ON at 4ºC with 100µl of Aβ40 diluted at 2µg/ml in NaHCO3. The plate 
was then washed with 200µl of Tris buffer saline 50mM + 0.05% Tween pH 7.4 (TTBS) 
and blocked with TBS-BSA 5% for 2h at RT. After washing, 100µl of each diluted 
serum or CSF sample was added in triplicate and incubated for 2h at RT. Serum 
samples were diluted at 1/200 with TBS-BSA 5% and CSF samples at 1/2 with TBS. 
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Samples from each dog were included in the same plate and 3 wells added with TBS-
BSA 5% were also used for background. After 5 washes, each well was incubated for 
30min at RT with a biotin rabbit anti-dog IgG (Lifespan bioscience, Derio, Spain) diluted 
with TBA-BSA 5% at 1/40000. After 6 washes, streptavidin diluted 1/4000 (Invitrogen, 
Madrid, Spain) was added and the ELISA kit amplification system (Invitrogen, Madrid, 
Spain) used for 2 min. Reaction was stopped with H2SO4 0.3M and OD registered at 
492nm. Data from IgG anti-Aβ titration of the different plates were normalized versus 
background. 
Quantification of Aβ40 and Aβ42 in plasma and CSF 
A specific ELISA kit (IBL international, Hamburg, Germany) was used for the detection 
of the total Aβ40 and Aβ42 in plasma and CSF. Following the manufacturer's guidelines, 
standard curves, controls and calibration were performed. Samples were also diluted 
1:3 for the measurement of CSF Aβ42, 1:25 for CSF Aβ40 and 1:5 for plasma Aβ40. After 
7 washes with PBS 100mM, pH7.4 containing 0.05% Tween-1%BSA, Aβ species were 
detected with anti- Aβ antibodies and measured at 450nm. 
Immunohistochemistry 
Immunohistochemistry was carried out on paraffin sections of brain tissues from stage 
II AD patients according to the Braak & Braak scale. Purified rabbit anti-Aβ antibodies 
from serum of v1, v2 and v3 immunized rabbits or purified dog anti-Aβ from immunized 
AC and immunized CDS dogs or commercial anti-Aβ antibodies (Dako, Glostrup, 
Denmark) were used as a primary antibody to detect Aβ plaques. Slices were 
deparaffined and pre-treated in formic acid for 2min. After endogenous peroxidase 
inhibition for 30min, slices were incubated with PBS 100mM, pH 7.4, containing 0.5% 
triton-X100-Normal goat serum 5%-BSA 5% as a blocking agent for 2h at RT. Purified 
primary antibodies were diluted with immunobuffer (PBS-5%-triton-X100-1%NGS-
1%BSA) at a correct concentration, or commercial anti-Aβ antibody diluted at 1/100 
were added an incubated ON at 4ºC. After 3 washes with PBS, samples were 
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incubated with 1/4000 diluted biotin rabbit anti-dog IgG (Lifespan bioscience, Derio, 
Spain) or 1/500 biotin mouse rabbit IgG for 2h at RT. Finally, after 3 washes, slices 
were incubated for 1h with ExtrAvidin peroxidase (1/250) and developed with 0.03% 
Diaminobenzidine (DAB) 0.006% H2O2 in PBS. Sections were dehydrated and 
mounted in DPX. Plaques were visualized by optical microscopy (Olympus America 
Inc., NY, USA) and micrographs were taken at 5x and 40x. 
Statistical analysis 
Kurtosis and skewness moments were calculated to verify the normal distribution of 
data. One-way ANOVA was performed to compare CSF and serum parameters 
between animal groups. To analyze differences in CSF and serum parameters during 
the treatment, two-way ANOVA was performed with two factors: Time with 5 levels 
(day 0, day 31, day 51, day 71 and day 131) of serum parameters, or with 3 levels (day 
0, day 51 and day 131) of CSF parameters, and Treatment (Non-treated, Placebo and 
Treated). When significant two-way interactions were observed, individual comparisons 
were performed using one-way ANOVAs followed by LSD post-hoc test. To quantify 
the association between two variables, a Pearson correlation was performed. When 
normality was not achieved, the values of all groups were compared using Non-
parametric analysis. In these cases, Kruskal-Wallis (KW) test followed by Mann-
Whitney test (MW) were used to compare dependent variable groups, and Sperman 
correlation to quantify the association between two variables. In all cases, p<0.05 was 
considered as significant. Results are expressed as a mean ± SEM. All analyses were 
performed with the programs SPSS 15 (IBM España, Madrid, Spain) and 
STATGRAPHICS (STSC Inc, Rockville, MD, USA). 
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RESULTS 
The v3 vaccine induces the highest antibody titration in rabbit 
To select the vaccine of major interest, an immunization study with v1, v2 and v3 was 
initially conducted in rabbits. To this end, 6 animals (n=2/group) were immunized with 
one vaccine following the immunization protocol selected for dogs. Blood samples were 
also extracted at the same selected time points until day 71, and anti-Aβ IgG 
measured. All three vaccines induced immunization, however the v3 composition gave 
the highest anti-Aβ IgG titration at day 71 (Fig. 3A). No side effect was detected in any 
animal. 
 
Dogs with light cognitive deficits have increased levels of plasma protein, 
platelets and Aβ levels 
When the 24 familiar dogs were evaluated at the beginning of the study (day 0) with 
our cognitive test, CDS was identified in 14 animals that presented light cognitive 
deficits (LCD, n=10) or severe cognitive deficits (SCD, n=4) (Table 2). The remaining 
10 animals classified as control were distributed with the 12 housed beagle dogs 
between the Adult Control group (AC, < 8 years, n=14) and the Old Control group (OC, 
n=8). 
During the whole study, all 16 biochemical and hematological parameters were found 
in the normal range in all animals. However, in the CDS group plasma protein levels 
and platelets was always higher and reticulocyte counts lower (p=0.004, 0.001 and 
0.002, respectively) (Data not shown). 
LCD dogs presented the highest Aβ40 plasma level (p=0.029) (Fig. 2A), and in all 
groups Aβ42 was lower than the plasma detection limit. In CSF, Aβ40 levels remained 
stable with aging and cognitive dysfunction, while Aβ42 levels only increased in the LCD 
dogs (p=0.018) (Fig. 2B,C). The high variability of their CSF Aβ42 values were strongly 
reduced once subdivided into: LCD1 dogs characterized by CSF Aβ40 and Aβ42 levels 
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similar to those of the Control and SCD groups and highest Aβ40 plasma values 
(p=0.009) (Fig. 2A, B, C); and LCD2 dogs with the highest CSF Aβ42 levels (p=0.018), 
and Aβ40 plasma and CSF levels similar to those of the Control and SCD groups (Fig. 
2C). When this new classification was applied to the plasma protein levels and platelet 
and reticulocyte counts, differences were observed in the LCD1 group (p=0.009, 0.024 
and 0.010, respectively) that did not correlate with Aβ40 or Aβ42 plasma and CSF 
values. Finally, only in controls Qalb positively correlated with age (R2= 0.56, p=0.0008) 
(Fig. 2D). 
 
Cognitive improvement of v3 immunized CDS dogs is accompanied by an 
increased plasma/CSF Aβ ratio  
The cognitive test was performed at days 0, 31, 51 and 131 in all dogs included in the 
v3 immunization study. At day 31 the immunized CDS dogs presented a 30% lower 
score (p=0.027) (Fig. 3B) that was maintained until day 51. At this day, a greater 
reduction of the score was observed in SCD dogs (45%, p=0.010) than in LCD ones 
(25%, p=0.043). A tendency to decrease was found in placebo animals, probably due 
to a closer and more frequent owner and veterinarian care. Due to a failing of several 
owner visits at the end of the study, only two immunized dogs could be evaluated until 
day 131. Compared to days 51, 31 and 0, both animals gave a lower score (Score 
values=11 and 9).  
To evaluate the molecular response to v3 immunization, all 16 hematological and 
biochemical blood parameters, as well as the blood and CSF Aβ and anti-Aβ40 IgG 
levels, were measured during the whole immunization period.  
Only the Alkaline Phosphatase (AP) value was not within the normal range in some 
familiar dogs (Table 3). Higher AP levels at days 71 and 130 (p=0.023 and 0.049, 
respectively) were detected in immunized CDS dogs compared to the placebo group, 
and were probably related to the irregular familiar feeding habits.  
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Qalb ratio remained similar in the AC and CDS groups during the whole study (Data 
not shown). 
In the v3 immunized AC dogs, Aβ40 plasma levels presented a tendency to increase 
until day 41. The same tendency, but with a larger variability, was observed until day 
51 in the v3 immunized CDS group (Fig. 4A). When compared with placebo, 
immunized AC dogs presented a similar Aβ40 CSF level between day 0 and 131, while 
Aβ42 value peaked at day 131 (p=0.034). In the immunized CDS group, Aβ40 CSF 
levels presented a tendency to decrease (Fig. 4B), and Aβ42 levels were lower at day 
51 (p=0.049) (Fig. 4C). When the ratio between plasma and CSF Aβ was obtained, a 
major tendency to increase was found in the immunized CDS dogs compared to 
placebo and AC immunized animals (Fig. 4D). When the analysis was performed with 
the immunized LCD1, the increasing values reached significant differences between 
LCD1 immunized dogs and Placebo and AC animals at day 51 (p=0.0211) (Fig. 4H).  
Significant plasma and CSF changes of the anti-Aβ40 IgG levels were observed in all v3 
immunized dogs during the whole follow-up,. Thus, in the immunized AC group, the 
anti-Aβ40 IgG serum levels reached a peak at day 31 and remained increased until day 
51 when compared to its pre-immune (p=0.0042) and Placebo group values 
(p=0.0079); at day 131 it returned to baseline value. Anti-Aβ40 IgG serum levels peaked 
at day 71 in immunized CDS dogs, higher that their pre-immune (p=0.0078) and the 
Placebo group values (p=0.0022) (Fig. 4E), being back to baseline at day 131. CSF 
Anti-Aβ40 IgG of immunized AC dogs were increased at day 51 compared to pre-
immune (p=0.0042) and placebo values (p=0.0078). CDS animals showed a similar 
tendency, but with lower levels (Fig. 4F). Both AC and CDS groups presented a 
positive correlation between serum and CSF anti-Aβ40 IgG levels (r2=0.53, p=0.0013) 
(Fig. 4I). However, only in the immunized CDS group and during the whole study, the 
anti-Aβ40 IgG and Aβ40 plasma ratio was 1/25, with a positive and linear correlation 
during the whole study (r2=0.362, p=0.0049)  (Fig. 4G). 
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Anti-Aβ40 IgG from v1, v2 or v3 immunized rabbits and v3 immunized dogs 
recognize human amyloid plaques  
In cerebral cortex of human with AD, immunohistochemistry with plasma anti-Aβ IgG 
isolated from the different immunized rabbits and dogs specifically stained amyloid 
plaques but not vessels. Purified antibodies from serum of v1 and v3 immunized 
rabbits presented a strong immunodetection of diffuse and core amyloid plaques, but 
the ones from v2 immunized rabbits only detected diffuse plaques (Fig. 5B, C, D). 
Purified dog anti-Aβ IgG presented a stronger staining of diffuse plaques than of core 
plaques (Fig. 5F, G). 
 
DISCUSSION 
Our data reinforce the CDS dog as a good natural AD model and fosters 
immunotherapy for Aβ pathologies, like canine CDS or human AD. Amyloid pathology 
associated with canine cognitive dysfunction presents a positive correlation between 
plaque maturation and degree of cognitive dysfunction [24,29]. In this study, CDS 
familiar dogs were classified based on their cognitive dysfunction degree and age in 
order to identify specific biomarkers of amyloid homeostasis of help for AD. 
Firstly, the higher values of plasmatic proteins and lower reticulocyte number found in 
the LCD1 group may reflect the oxidative damage and inflammatory processes 
involved in the first stages of the disease. Initial amyloid deposition, related to oxidative 
stress and inflammation [17,30], might then be associated with alterations of 
hematological parameters present in aging and oxidative damage [31]. Secondly, we 
also found higher plasma levels of Aβ40 in the LCD1 group, which would indicate a 
relationship between plasma Aβ40 and cognitive dysfunction. This hypothesis, 
approached in rodents and dogs with conflicting results [32–34], is difficult to validate 
due to the Aβ hydrophobic properties and its important binding to plasma proteins, 
such as albumin, that cause analytical interferences and variability. 
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Similarly, although no relationship has been established between Aβ plasma levels and 
BBB permeability, several studies in human beings, dogs and rodents describe an 
increased BBB permeability with aging [35,36]. However, besides the association 
between BBB permeability and inflammatory diseases [37–40], no correlation has been 
established between BBB permeability and cognitive dysfunction [39,41]. Our results 
evidence that BBB permeability is only increased in aging healthy dogs, and remains 
stable in CDS dogs, similar to young matched animals, reflecting a lack of BBB 
alteration associated with cognitive dysfunction.  
In fact, our findings reinforce the familiar dog to help decipher the early events of the 
diffuse Aβ plaque maturation and explain its relationship with human cognitive 
dysfunction [13]. For example, together with differences in platelet levels in the LCD1 
group, a comparison between these dogs and the human MCI [42], specifically with 
amnesic MCI, in which the disease progress to AD might bring new advances. 
Finally, we found no correlation between CSF Aβ42 and cognitive dysfunction, and only 
higher Aβ42 levels in the LCD group that could be used as a marker of early CDS. CSF 
Aβ42 level, a biomarker for AD diagnosis and monitoring correlates negatively with total 
Aβ load in the brain, and also with cognitive dysfunction stage [43–45]. On the other 
hand, our CSF results are similar to those described recently in control housed beagles 
showing that, between the age of 4 and 16, CSF Aβ40 remains constant and Aβ42 
presents a slight decrease [14]. However, the lack of data regarding Aβ42 and Aβ40 
plasma variation makes difficult a further amyloid homeostasis explanation. Different 
dynamic [3] and Aβ aggregation progression processes [46–49] may explain these 
differences with the studies in human beings. 
Despite the differences between some CDS and AD biomarkers, we can establish a 
relationship between canine cognitive dysfunction and age-related amyloid biomarkers. 
The dog cognitive improvement associated with changes in several biomarkers verifies 
the potential of our Aβ vaccine for CDS treatment. Our findings also confirm the interest 
of immunotherapy to stimulate Aβ peptide clearance across the BBB for a rapid and 
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safe cognitive benefit in CDS dogs. Thus, as early as 30 days after initial v3 
immunization, plasma Aβ40 was increased and both CSF Aβ40 and Aβ42 decreased. 
This was followed by an increased Aβ plasma/CSF ratio in the LCD1 group at day 51. 
In the immunized adult control dogs, plasma Aβ40 was also increased but remained 
constant in CSF. Therefore, an Aβ40 plasma/CSF increased ratio would represent a 
good marker of plasma clearance. 
These modifications in plasma Aβ40 were accompanied by a 10-fold increased serum 
anti-Aβ40 IgG, with a peak at day 71 in CDS animals and at day 51 in adult control 
dogs. Only in this last group, anti-Aβ40 IgG was significantly increased in CSF at day 
51, with an abundance of 0.01% of serum level, whereas in CDS animals, its increase 
was not significant. Compared to adult control dogs, the reduced immunogenic 
response in aged dogs, similar to humans [50], explain the delay and lower level of 
their serum IgG peak, and the discrete IgG presence in CSF. Anyway, the 
interrelationship of the processes taking place in CSF and blood seems to be similar in 
all groups of animals, as shown by the related temporal changes of amyloid 
parameters and IgG levels in both compartments to facilitate Aβ clearance. This is of 
special importance in view of the concern regarding the efficacy of immunotherapy in 
elderly patients with also a weak immune system [51]. 
The plasma anti-Aβ40 IgG and Aβ40 ratio of 1/25 was only found in immunized CDS 
dogs, suggesting the direct formation of antigen-antibody complexes to stimulate the 
sink effect from CNS to the periphery [52]. A variety of studies performed with different 
antibodies that recognize N and C terminal Aβ fragments argue for the same 
mechanism [53,54]. Because differences in antibody recognition of the Aβ peptide 
define its ability to cross the BBB, our v3 vaccine includes a variety of peptides that 
induce an antibody mixture to interact with the N or C Aβ terminal. So, the N-Aβ 
antibody recognition will mostly take place at the periphery, forming ag-ab complexes 
for the sink effect. Meanwhile, both N- and C-Aβ antibody recognition will favor the 
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central recognition of Aβ monomers, oligomers and mainly diffuse plaques, due to the 
maturation affinity process of B cells during the immunization period [55,56]. 
BBB damage is observed in many neuropathologies like AD and its permeability 
increases with aging. However, the lack of BBB alteration in CDS dogs may be related 
to the absence of mature plaques, or to LRP1 and RAGE modifications in their function 
of Aβ clearance [57–59]. In any case, with immunization, the BBB active Aβ removal 
would increase and facilitate cognitive improvement.   
The v3 vaccine antigen builds a boost of antibodies, together with the possibility of a B-
cell response by the C-Aβ epitope [60]. Irregular familiar feeding habits are considered 
the main cause of the dog higher phosphatase alkaline levels because of its role in the 
digestion and absorption of fats in the intestinal tract [61] and cannot be related to the 
immunization. The risk of an inflammatory response was also fully discarded by the 
clinical follow-up of all animals and the normality of the frequent plasma and CSF 
analyses.  
 
CONCLUSIONS 
In conclusion, we have designed and validated in old dogs with graded cognitive 
dysfunction and a weak immune system the efficacy and security of a new vaccine 
considered a good candidate for human AD prevention and treatment. This study also 
confirms familiar dogs as a good natural model of AD, with the aim of developing 
innovative and reliable therapies. In these animals, the behavioral, CSF and plasma 
studies are rapid and easy to perform, and allow to decipher the intrinsic mechanisms 
involved in Aβ physiopathology. This will shed light on our understanding of human 
amyloidosis.  
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ABBREVIATIONS 
ag-ab = antigen-antibody 
AC = Adult Control 
AP = Alkaline Phosphatase 
CDS = Cognitive dysfunction syndrome 
CSF = Cerebrospinal fluid 
EDTA = Ethylenediaminetetraacetic acid 
i.v = intravenously 
Qalb = Albumin quotient 
LCD = light cognitive deficit   
OC = Old Control 
s.c = subcutaneously 
SCD = severe cognitive deficit 
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FIGURE LEGENDS 
Fig. 1 Schematic timeline of canine immunization study. Horizontal arrow indicates the 
immunization period during which 6 doses of v3 vaccine or were subcutaneously 
injected. Vertical arrows indicate the cognitive evaluation days and the CSF and serum 
extraction days. The same immunization period and blood extraction protocol was used 
in the study performed in rabbits to select the best vaccine composition. 
Fig. 2 Plasma Aβ40 and CSF Aβ40 and Aβ42 levels in control (AC and OC) dogs and 
CDS dogs (LCD and SCD). In LCD dogs, plasma Aβ40 levels (A) are different (p=0.029) 
and also CSF Aβ42 levels (C) (p=0.018). Two subgroups are observed in this LCD 
group: LCD1, the dogs with higher plasma Aβ40 levels (p=0.009) and LCD2, the dogs 
with higher CSF Aβ42 levels (p=0.018). CSF Aβ40 level is similar in control and CDS 
dogs (B).  
Fig. 3 Anti-Aβ40 levels in v1, v2 and v3 immunized rabbits during the immunization 
period (A) and cognitive changes of v3 immunized CDS dogs (B). Anti-Aβ40 IgG levels 
in immunized rabbits reach a peak at day 51. Rabbits immunized with the v3 vaccine, 
present higher antibody levels. The dog cognitive changes during the immunization 
study was evaluated by the veterinarian with a validated Cognitive test performed at 
days 0, 31, 51, and 131. At day 31, significant changes were already detected in all 
immunized CDS dogs (p=*0.027) (B). 
Fig. 4 Plasma Aβ40, CSF Aβ40 and Aβ42, and antibody levels during the whole study. A 
tendency to increase of plasma Aβ40 in AC and CDS dogs (A), is observed but only a 
marked decrease of CSF Aβ40 and Aβ42 levels in CDS dogs after the immunization 
period (*p=0.049 for A β42) (B,C). The ratio between those levels is only increased in 
the LCD dogs when we compare the groups at days 0 and 51, (H). Anti-Aβ40 IgG is 
detected in serum and CSF at day 30 after the first boost (levels over 0.24nm) (E-F). In 
AC dogs the highest level is observed at day 51 (#p=0.0042 vs pre-immune levels; 
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*p=0.0079 vs placebo levels) (E) and  in CDS dogs at day 71 (#p=0.0078 vs pre-
immune levels; (*p=0.0022 vs placebo levels). CSF Anti-Aβ40 IgG is detected in all dogs 
with significant differences at day 31 in AC dogs (#p=0.0042 vs pre-immune values; 
*p=0.0078 vs placebo values) (F). Serum and CSF antibodies are positively correlated 
in AC and CDS dogs (G). However, plasma Aβ40 and plasma anti-Aβ40 IgG levels are 
only correlated in CDS dogs, (I). 
Fig. 5 Detection of Aβ plaques in AD human brain with purified antibodies from 
immunized rabbits and dogs. Micrographs at 5x and 40x. Antibodies from v1 (Aβ40) or 
v3 (Aβ40+ Aβx-40) immunized rabbits detect diffuse and core plaques (B, D). Antibodies 
from v2 (Aβx-40) immunized rabbits only detect diffuse plaques (C). Antibodies from v3 
immunized dogs only detect diffuse plaques. Plaque detection with IgG from AC (F) or 
CDS dogs (G) is similar. Positive control with a commercial antibody (A, E). 
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TABLES 
 
Table 1 Diversity of the dogs  
 
ID 
    
Breed 
 
Sex 
 
Age 
 
Screening 
 group 
 
Immunization 
group 
1 Housed beagle dog Male 2 AC Immunized AC 
2 Housed beagle dog Male 2 AC Immunized AC 
3 Housed beagle dog Male 3 AC Immunized AC 
4 Housed beagle dog Male 4 AC Immunized AC 
5 Housed beagle dog Male 4 AC Immunized  AC 
6 Housed beagle dog Male 6 AC Immunized  AC 
7 Housed beagle dog Male 4 AC Placebo 
8 Housed beagle dog Male 2 AC Placebo 
9 Housed beagle dog Male 2 AC Placebo 
10 Housed beagle dog Male 3 AC  
11 Housed beagle dog Male 6 AC  
12 Housed beagle dog  Male 8 OC  
13 Belgian Shepherd dog  Female 6 AC  
14 Rottweiler Female 7 AC  
15 Mixed breed Female 6 AC  
16 Mixed breed Male 10 OC  
17 Mixed breed Female 10 OC  
18 Mixed breed Male 12 OC  
19 Catalan shepherd breed Male 12 OC  
20 Beagle  Male 13 OC  
	  	  
	  
32	  
  
21 Mixed breed Male 13 OC  
22 Catalan shepherd dogs Male 14 OC  
23 Mixed breed Female 14 LCD   
24 Kurzhaar Female 12 LCD   
25 Golden Retriever  Female 11 LCD  Placebo 
26 Mixed  Female 14 LCD  Placebo 
27 Catalan shepherd Male  15 LCD  Immunized CDS 
28 Mixed breed Male 15 LCD  Immunized CDS 
29 Boxer  Male 10 LCD Immunized CDS 
30 Mixed breed Female 13 LCD  Immunized CDS 
31 Mixed breed Male 14 LCD  Immunized CDS 
32 Beagle  Male 14 LCD  Immunized CDS 
33 Mixed breed Male 15 SCD  Placebo 
34 Golden Retriever Female 15 SCD  Immunized CDS 
35 Mixed breed Female 18 SCD  Immunized CDS 
36 Mixed breed Male 15 SCD Immunized CDS 
12 housed beagle and 24 familiar dogs were used in the study. In this last group, 14 animals 
identified as CDS by their neurological records and cognitive test were subdivided into two 
groups according to their total score: 10 dogs identified with Light Cognitive Dementia (LCD) 
and 4 with Severe Cognitive Dementia (SCD), (See details in Table1). For their 
characterization, they were matched with Adult Control (AC, n= 14) and Old Control dogs 
(OC, n= 8). For the Immunization study 12 CDS dogs and 9 housed beagle dogs were 
included, and 9 CDS (Immunized CDS) and 6 housed beagle dogs (Immunized AC) received 
the v3 vaccine. 3 CDS dogs and 3 AC received Saline solution + Alum (Placebo group).	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Table 2. Cognitive Test 
 
 
 
Items 
 
Score 
 
Items 
 
Score 
 
Items 
 
Score 
 
   (1) Walking 
Normal 
Trudging 
    Abnormal, one direction,  circling 
 
 
1 
3 
5 
 
 (4) Life rhythm 
       Normal 
       Rest and sleep over during the day  
       Switches between insomnia & 
       hypersomnia 
       Restless at bedtime 
 
 
 
1 
2 
3 
 
5 
 
 
 (7) Learned specific 
       behavior 
      Normal (unchanged) 
      Random responses 
      Decreased response 
 
 
 
1 
3 
5 
 
 
(2) Posture/ emotional of expression 
  Normal 
  Decrease of body language 
  Abnormal, loss of body language 
 
 
 
1 
3 
5 
 
(5) Play behavior 
      Normal 
      Increase 
      Decrease 
 
 
 
1 
3 
5 
 
 (8) Adaptive capabilities 
        Normal 
        Retreats from novel situation 
        Unable to accept changes in   
        routine 
        Looks indifferent to changes 
 
 
1 
2 
3 
 
5 
 
 
(3) Elimination behavior 
      Normal 
      Defecate and urinate at home: 
      occasionally in a small scattered  
      amount 
      Loss control of sphincters: 
      defecate and urinate outside of 
      sleeping area 
      Loss control of sphincters: 
      defecate and urinate inside of 
      sleeping area 
 
 
1 
3 
 
 
4 
 
 
5 
 
(6) Exploratory behavior 
      Normal 
      Decrease (disorientation   
      expectance   posture, etc) 
      Increase (obsessive  exploration of   
      the same place, including oral  
      exploration) 
 
 
1 
3 
 
5 
 
 
 (9) Interaction with other 
        animals or with owners 
         Normal 
         Decreased (loss of relationship 
         with humans or other animals) 
         Complete loss relationship with 
         owners 
 
 
 
1 
3 
 
5 
Total score in the 9 items test: <12= normal; 12-26= light cognitive deficits SCD; >26=severe cognitive 
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Table 3. Hematological and biochemistry parameters during immunization study 
 
 
Hematological parameters 
 
Placebo 
 
Immunized AC  
  
 
Immunized CDS 
 
Range 
 
White blood cells 
 
6.49±0.68-10.88±1.58 
 
6.08± 0.99-11.10±0.416 
 
6.99±1.15-0.86±1.26 
 
5.05-16.76 
 
Lymphocytes 
 
1.30±0.15-2.20±0.66 
 
1.05±0.16-2.33±0.74 
 
1.07±0.21-2.30±0.54 
 
1.05-5.10 
 
Monocytes 
 
0.42±0.81-1.18±0.19 
 
0.45±0.11-0.98±0.15 
 
0.43±0.05-1.04±0.15 
 
0.16-1.12 
 
Neutrophils 
 
4.38±0.50- 13.00±8.52 
 
4.21±0.52-8.06±0.13 
 
4.18±1.59-6.67±1.38 
 
2.95-11.64 
 
Eosinophil’s 
 
0.22±0.05-0.37±0.10 
 
0.31±0.04-0.72±0.16 
 
0.19±0.08-0.43±0.11 
 
0.06-1.23 
 
Basophils 
 
0.02±0.004-0.06±0.01 
 
0.02±0.005-0.06±0.01 
 
0.02±0.006-0.05±0.01 
 
0.00-0.10 
 
Hematocrit 
 
46.88±2.51-48.83±1.07 
 
47.06±1.46-57.90±1.13 
 
41.27±4.73-47.82±6.57 
 
37.3-61.7 
 
Hemoglobin 
 
14.45±0.48-16.13±0.55 
 
14.96±0.41-18.63±0.41 
 
13.700±1.35-5.27±0.56 
 
13.1-20.5 
 
Reticulocytes 
 
29.86±8.71-42±4.80 
 
37.80±4.08-64.13±9.95 
 
29.81±4.49-43.41±7.93 
 
6.6-100.7 
 
Platelets 
 
 
 
178.33±31.07-381.25(±84.86 
 
221.67±5.17-18.33±25.20 
 
285.50±40.77-343±41.51 
 
148-484 
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Biochemical 
parameters 
 
Placebo 
 
Immunized AC  
  
 
Immunized CDS 
 
Range 
 
Alkaline Phosphatase (AP) 
 
105.33±6.32-238.83±48.01 
 
89.33±18.50-165.00±72.39 
 
403.71±136.59-760.71±256.45 
 
23-212 
 
Glutamate  Pyruvate       
Transaminase (GPT) 
 
41.33±9.49-119.833±51.46 
 
39.67±9.82-80.67±18.80 
 
99.66±22.44-161.66±25.26 
 
0-100 
 
Creatinine 
 
0.793±0.11-1.10±0.07 
 
0.79±0.08-1.04±0.02 
 
0.87±0.11-1.13±0.15 
 
0.5-1.8 
 
Urea 
 
33.25±3.62-64.31±15.92 
 
24.43±3.76-58.5±3.77 
 
40.52±8.98-106.21±36.67 
 
18-60 
 
Total protein 
 
6.20±0.115-6.66±0.287 
 
5.90±0.06-6.80±0.15 
 
6.55±0.13-7.45±0.21 
 
5.2-8.2 
 
Glucose 
 
100.50±12.41-115.66±6.35 
 
98.00±10.01-128±6.50 
 
89.80±4.54-107.28±5.35 
 
74-143 
Biochemical and hematological parameters measured during the immunization study with their minimum and 
maximum values (±s.d.). Values in bold of alkaline phosphatase present significant differences in familiar dogs	  
